Studying whether a wearable device can predict decline in people with CIDP
Tests the Actimyo wearable device in adults with chronic inflammatory demyelinating polyneuropathy.
Plain-language title generated from the registry record
Registry title: Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
Key facts
- Where
- Liège, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06183645, who can take part
Where in Belgium
- CHR CitadelleLiège, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Liege
- Trial code
- NCT06183645
- Record updated
- 12 February 2025
- Original description
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis.Read full original descriptionShow less
ActiCIDP : Exploratory Study on the Feasibility of Predicting CIDP Patients' Evolution Decline During Intravenous Immunoglobulins Treatment Adaptation.
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis.
The investigators plan to include a group of approximately 40 patients with CIDP.
The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Inclusion: Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2; Treated with IVIg (≤1g/kg/3-8week); Clinically Stable disease for 3 months (according to treating physician opinion); No treatment withdrawal failure within 1 year; Age over 18 years.
Exclusion: Surgery or serious traumatic injury ≤ 6 months; Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy; Significant cognitive or communication disorders; Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment; Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety; Non ambulant patient; Current participation to a therapeutic trial; Pregnancy or breastfeeding.